WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
SHANGHAI, Aug. 9 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.
(NYSE: WX) today announced shareholder resolutions adopted at its annual
general meeting of shareholders held in Hong Kong on August 7, 2009.
At the meeting, WuXi PharmaTech shareholders approved the re-election of
incumbent Class B directors Xuesong Leng, Zhaohui Zhang, and Ning Zhao, each
to serve a three-year term.
In addition, the WuXi shareholders approved an amendment to the Company's
Memorandum of Articles and Association that revises Article 82 so that it no
longer requires a Special Resolution be obtained for an office of a Director
to be considered vacated.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
device R&D outsourcing company, with operations in China and the United States.
As a research-driven and customer-focused company, WuXi PharmaTech provides a
broad and integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi PharmaTech's services
are designed to assist its global partners in shortening the cycle and
lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating
subsidiaries are known as WuXi AppTec. For more information, please visit:
http://www.wuxiapptec.com .
For more information, please contact:
WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com
Stephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com
